ValueAct Capital Boosts Stake In Valeant Pharmaceuticals As Stock Skids

Mar 17 2017 | 10:59pm ET

Jeff Ubben's activist hedge fund ValueAct Capital has raised its stake in embattled Canadian drug company Valeant Pharmaceuticals just days after Bill Ackman’s Pershing Square threw in the towel and booked a $3 billion loss on its position in the stock.

ValueAct bought $30 million worth of Valeant shares this past week, according to a Bloomberg article citing a disclosure by the company on Thursday. It is a miniscule amount compared to ValueAct’s prior positions in the stock, which it has owned since 2006, but carries symbolic value now that Pershing has left. 

With this latest purchase, ValueAct now owns 5.2% of Valeant, up from 4.4% last quarter, and one of the company’s two largest shareholders alongside John Paulson’s Paulson & Co., which owns 5.7%. ValueAct partner Robert Hale remains a member of Valeant’s board.

Valeant's’ share price, already down more than 95% since its July 2015 high, fell more than 10% further on the Pershing news but recovered half that amount to close the week at just over $11. 


In Depth

An Interview With Harvest Volatility Management's Rick Selvala

Mar 23 2017 | 5:39pm ET

Several years of extremely low interest rates have pushed some investors into equities...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

SEI: Private Debt Coming Into Its Own

Mar 8 2017 | 9:24pm ET

The explosive growth of private debt over the past few years has caused the lines...

 

From the current issue of